| Literature DB >> 15120729 |
Q Liu1, K Rand, H Derendorf.
Abstract
Pharmacokinetic-pharmacodynamic (PK-PD) modelling was used to study the impact of the pharmacokinetics of tazobactam on the antimicrobial effect of piperacillin-tazobactam combinations. An in vitro experiment using a novel dilution system was performed to compare the effects of two conditions of the combination therapy against Escherichia coli ATCC35218, a beta-lactamase producing bacterium. Both conditions simulated the same initial concentrations of piperacillin and tazobactam, but different elimination half-lives for tazobactam. The killing and regrowth kinetics of E. coli clearly indicated that there is a difference in the antimicrobial effects when there is a difference in the pharmacokinetics of tazobactam in the combination therapy. The results show that for equal piperacillin exposure, different tazobactam half-lives will have a significant effect on antimicrobial outcome.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15120729 DOI： 10.1016/j.ijantimicag.2003.10.012
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN： 0924-8579 Impact factor: 5.283